Literature DB >> 35322387

Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage I-III colorectal cancer: a retrospective cohort study.

Lulu Ma1,2,3, Wenya Li1,2,3, Ningquan Liu1,2,3, Zhijie Ding1,2,3, Jianchun Cai1,2,3, Yiyao Zhang4,5,6.   

Abstract

There are no ideal biomarkers including the TNM stage that can accurately predict the recurrence of colorectal cancer (CRC) and the benefit of chemotherapy for stage II patients. Here, 451 CRC patients were divided into three groups according to preoperative levels of prothrombin time (PT) and CEA to analyze the value of these indexes in predicting postoperative recurrence in different TNM stages. Preoperatively elevated levels of PT and CEA were significantly associated with a high 5-year cumulative recurrence rate (CRR) and short recurrence-free survival (RFS). According to PT and CEA levels, the 5-year CRR and RFS differed significantly among the High-risk (PT ≥ 12.65 s and CEA ≥ 10.175 ng/ml), Middle-risk (PT ≥ 12.65 s or CEA ≥ 10.175 ng/ml), and Low-risk (PT < 12.65 s and CEA < 10.175 ng/ml) groups (p < 0.001). In the same TNM stage, the 5-year CRR of the High-risk group was significantly higher and the RFS was markedly shorter than those in the Low-risk and even those in stage III (p < 0.001). In the subgroup of early stage (stage I and II), the 5-year CRR of the High-risk group was significantly higher and the RFS was significantly shorter than those in stage IIIA and IIIB (p < 0.001), which is similar to IIIC. In conclusion, preoperatively elevated levels of serum PT and CEA were reliable predictors of postoperative high-risk recurrence in CRC and combined with TNM stage precisely identify postoperative recurrence CRC patients in stage I-III and the benefit of adjuvant chemotherapy for patients with stage II CRC.
© 2022. Italian Society of Surgery (SIC).

Entities:  

Keywords:  Biomarkers; CEA; Colorectal cancer; Prothrombin time (PT); Recurrence

Mesh:

Substances:

Year:  2022        PMID: 35322387     DOI: 10.1007/s13304-022-01268-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  26 in total

Review 1.  Systemic therapy for colorectal cancer.

Authors:  Jeffrey A Meyerhardt; Robert J Mayer
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

2.  Elevation of Pretreatment Carcinoembryonic Antigen Level as a Prognostic Factor for Colon Cancer: Incorporating a C Stage in the AJCC TNM Classification.

Authors:  Ramzi Amri; David L Berger
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

3.  Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Authors:  Yifan Peng; Zhiwei Zhai; Zhongmin Li; Lin Wang; Jin Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  G Argilés; J Tabernero; R Labianca; D Hochhauser; R Salazar; T Iveson; P Laurent-Puig; P Quirke; T Yoshino; J Taieb; E Martinelli; D Arnold
Journal:  Ann Oncol       Date:  2020-07-20       Impact factor: 32.976

5.  Prognostic Subgroups among Patients with Stage II Colon Cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

6.  Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.

Authors:  Ofer Margalit; Ronac Mamtani; Yu-Xiao Yang; Kim A Reiss; Talia Golan; Naama Halpern; Dan Aderka; Bruce Giantonio; Einat Shacham-Shmueli; Ben Boursi
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

7.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

8.  Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).

Authors:  Lin Zhang; Juan Ye; Qiuyun Luo; Miaohuan Kuang; Minjie Mao; Shuqin Dai; Xueping Wang
Journal:  Cancer Manag Res       Date:  2020-07-03       Impact factor: 3.989

9.  Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.

Authors:  Tsuyoshi Konishi; Yoshifumi Shimada; Meier Hsu; Lauren Tufts; Rosa Jimenez-Rodriguez; Andrea Cercek; Rona Yaeger; Leonard Saltz; J Joshua Smith; Garrett M Nash; José G Guillem; Philip B Paty; Julio Garcia-Aguilar; Mithat Gonen; Martin R Weiser
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort.

Authors:  Erik Osterman; Artur Mezheyeuski; Tobias Sjöblom; Bengt Glimelius
Journal:  Ann Surg Oncol       Date:  2020-01-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.